Brief: Graphite Bio Announces U.S. FDA Fast Track Designation Granted To Gph101 For The Treatment Of Sickle Cell Disease

LENZ Therapeutics

03/05/2022 13:27

May 3 (Reuters) - Graphite Bio Inc  GRPH.O :
    * GRAPHITE BIO ANNOUNCES U.S. FDA FAST TRACK DESIGNATION
GRANTED
TO GPH101 FOR THE TREATMENT OF SICKLE CELL DISEASE
    * GRAPHITE BIO ANNOUNCES U.S. FDA FAST TRACK DESIGNATION
GRANTED
TO GPH101 FOR THE TREATMENT OF SICKLE CELL DISEASE
    * GRAPHITE BIO INC SAYS GPH101 IS AN INVESTIGATIONAL
NEXT-GENERATION GENE-EDITED THERAPY DESIGNED TO POTENTIALLY
PROVIDE A ONE-TIME CURE FOR PATIENTS

Source text for Eikon:  ID:nBw7h2mm3a 
Further company coverage:  GRPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))